drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00087 | DB12332 | 599 | 1,619 | [
"DDInter41",
"DDInter1626"
] | Alemtuzumab | Rucaparib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
599,
24,
1619
]
],
[
[
599,
24,
259
],
[
259,
24,
1619
]
],
[
[
599,
24,
151
],
[
151,
63,
1619
]
],
[
[
599,
63,
1257
],
[
1257,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/... |
DB00092 | DB09074 | 58 | 1,362 | [
"DDInter40",
"DDInter1327"
] | Alefacept | Olaparib | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
58,
24,
1362
]
],
[
[
58,
24,
725
],
[
725,
63,
1362
]
],
[
[
58,
24,
896
],
[
896,
24,
1362
]
],
[
[
58,
63,
599
],
[
599,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposi... |
DB09078 | DB11110 | 1,228 | 603 | [
"DDInter1036",
"DDInter1115"
] | Lenvatinib | Magnesium citrate | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1228,
24,
603
]
],
[
[
1228,
64,
57
],
[
57,
24,
603
]
],
[
[
1228,
63,
789
],
[
789,
24,
603
]
],
[
[
1228,
24,
484
],
[
484,
6... | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Lenvatinib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Fos... |
DB00224 | DB09082 | 215 | 659 | [
"DDInter917",
"DDInter1934"
] | Indinavir | Vilanterol | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
215,
24,
659
]
],
[
[
215,
24,
1220
],
[
1220,
23,
659
]
],
[
[
215,
63,
1351
],
[
1351,
23,
659
]
],
[
[
215,
25,
175
],
[
175,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flu... |
DB01208 | DB11348 | 945 | 1,065 | [
"DDInter1705",
"DDInter279"
] | Sparfloxacin | Calcium Phosphate | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
945,
24,
1065
]
],
[
[
945,
40,
246
],
[
246,
24,
1065
]
],
[
[
945,
40,
246
],
[
246,
40,
1176
],
[
1176,
24,
1065
]
],
[
[
945,
... | [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may ... | Sparfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Sparfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause ... |
DB00072 | DB00242 | 550 | 1,064 | [
"DDInter1846",
"DDInter392"
] | Trastuzumab | Cladribine | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
550,
25,
1064
]
],
[
[
550,
24,
1270
],
[
1270,
63,
1064
]
],
[
[
550,
63,
1253
],
[
1253,
24,
1064
]
],
[
[
550,
25,
779
],
[
779,
... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Cladribine
Trastuzumab may cause a moderate interaction that could... |
DB00514 | DB06603 | 506 | 39 | [
"DDInter527",
"DDInter1387"
] | Dextromethorphan | Panobinostat | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
506,
24,
39
]
],
[
[
506,
24,
1627
],
[
1627,
63,
39
]
],
[
[
506,
24,
272
],
[
272,
24,
39
]
],
[
[
506,
63,
867
],
[
867,
24,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlor... |
DB00526 | DB00570 | 1,555 | 147 | [
"DDInter1355",
"DDInter1936"
] | Oxaliplatin | Vinblastine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
1555,
24,
147
]
],
[
[
1555,
63,
134
],
[
134,
24,
147
]
],
[
[
1555,
6,
5912
],
[
5912,
45,
147
]
],
[
[
1555,
24,
739
],
[
739,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Oxaliplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Vinblastine (Compound)
Oxaliplatin ma... |
DB00899 | DB06691 | 411 | 849 | [
"DDInter1579",
"DDInter1155"
] | Remifentanil | Mepyramine | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
411,
24,
849
]
],
[
[
411,
63,
1594
],
[
1594,
24,
849
]
],
[
[
411,
24,
272
],
[
272,
24,
849
]
],
[
[
411,
24,
412
],
[
412,
6... | [
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine ... |
DB00384 | DB01225 | 1,275 | 500 | [
"DDInter1859",
"DDInter645"
] | Triamterene | Enoxaparin | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
1275,
24,
500
]
],
[
[
1275,
21,
28778
],
[
28778,
60,
500
]
],
[
[
1275,
24,
222
],
[
222,
24,
500
]
],
[
[
1275,
24,
714
],
[
714,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (... | Triamterene (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Enoxaparin (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases w... |
DB00029 | DB10344 | 25 | 992 | [
"DDInter99",
"DDInter818"
] | Anistreplase | Ginger | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
25,
24,
992
]
],
[
[
25,
64,
1578
],
[
1578,
24,
992
]
],
[
[
25,
25,
1421
],
[
1421,
63,
992
]
],
[
[
25,
24,
1347
],
[
1347,
2... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",... | Anistreplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Anistreplase may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate intera... |
DB01087 | DB09276 | 1,520 | 381 | [
"DDInter1520",
"DDInter1682"
] | Primaquine | Sodium aurothiomalate | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Major | 2 | [
[
[
1520,
25,
381
]
],
[
[
1520,
24,
1683
],
[
1683,
24,
381
]
],
[
[
1520,
25,
1593
],
[
1593,
24,
381
]
],
[
[
1520,
62,
112
],
[
112,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Primaquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotin... |
DB06081 | DB14730 | 1,046 | 1,412 | [
"DDInter286",
"DDInter264"
] | Caplacizumab | Calaspargase pegol | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1046,
24,
1412
]
],
[
[
1046,
25,
792
],
[
792,
24,
1412
]
],
[
[
1046,
64,
1347
],
[
1347,
24,
1412
]
],
[
[
1046,
63,
1274
],
[
1274... | [
[
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
... | Caplacizumab may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Caplacizumab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause... |
DB00208 | DB15233 | 1,018 | 1,650 | [
"DDInter1804",
"DDInter142"
] | Ticlopidine | Avapritinib | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1018,
25,
1650
]
],
[
[
1018,
24,
557
],
[
557,
24,
1650
]
],
[
[
1018,
24,
1512
],
[
1512,
25,
1650
]
],
[
[
1018,
25,
4
],
[
4,
... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"D... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Diclof... |
DB00692 | DB04844 | 274 | 843 | [
"DDInter1448",
"DDInter1778"
] | Phentolamine | Tetrabenazine | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
274,
24,
843
]
],
[
[
274,
21,
29335
],
[
29335,
60,
843
]
],
[
[
274,
24,
1376
],
[
1376,
24,
843
]
],
[
[
274,
63,
530
],
[
530,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotensive"
],
[
"Hypotensive",
"{u} (Side Effe... | Phentolamine (Compound) causes Hypotensive (Side Effect) and Hypotensive (Side Effect) is caused by Tetrabenazine (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases wh... |
DB00771 | DB06691 | 262 | 849 | [
"DDInter397",
"DDInter1155"
] | Clidinium | Mepyramine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
262,
24,
849
]
],
[
[
262,
63,
1594
],
[
1594,
24,
849
]
],
[
[
262,
24,
272
],
[
272,
24,
849
]
],
[
[
262,
24,
1116
],
[
1116,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Ch... |
DB00222 | DB08870 | 245 | 850 | [
"DDInter825",
"DDInter228"
] | Glimepiride | Brentuximab vedotin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
245,
24,
850
]
],
[
[
245,
24,
1338
],
[
1338,
24,
850
]
],
[
[
245,
24,
1033
],
[
1033,
63,
850
]
],
[
[
245,
63,
305
],
[
305,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic aci... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00975 | DB01175 | 1,317 | 318 | [
"DDInter573",
"DDInter672"
] | Dipyridamole | Escitalopram | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1317,
24,
318
]
],
[
[
1317,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1317,
21,
29276
],
[
29276,
60,
318
]
],
[
[
1317,
64,
834
],
[
834,
... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Dipyridamole (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Escitalopram (Compound)
Dipyridamole may lead to a major... |
DB00307 | DB00393 | 1,101 | 854 | [
"DDInter202",
"DDInter1295"
] | Bexarotene | Nimodipine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Moderate | 1 | [
[
[
1101,
24,
854
]
],
[
[
1101,
24,
84
],
[
84,
40,
854
]
],
[
[
1101,
63,
1428
],
[
1428,
40,
854
]
],
[
[
1101,
6,
8374
],
[
8374,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine (Compound) resembles Nimodipine (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nimodipine (Compound... |
DB01320 | DB06176 | 651 | 1,342 | [
"DDInter783",
"DDInter1616"
] | Fosphenytoin | Romidepsin | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
651,
24,
1342
]
],
[
[
651,
63,
112
],
[
112,
23,
1342
]
],
[
[
651,
25,
1491
],
[
1491,
63,
1342
]
],
[
[
651,
63,
820
],
[
820,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Fosphenytoin may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin ... |
DB00046 | DB00188 | 1,179 | 168 | [
"DDInter940",
"DDInter222"
] | Insulin lispro | Bortezomib | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Moderate | 1 | [
[
[
1179,
24,
168
]
],
[
[
1179,
24,
1040
],
[
1040,
62,
168
]
],
[
[
1179,
24,
590
],
[
590,
63,
168
]
],
[
[
1179,
63,
305
],
[
305,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide a... |
DB08865 | DB11581 | 1,593 | 1,456 | [
"DDInter448",
"DDInter1926"
] | Crizotinib | Venetoclax | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1593,
25,
1456
]
],
[
[
1593,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
1593,
63,
536
],
[
536,
24,
1456
]
],
[
[
1593,
25,
1476
],
[
1476... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Crizotinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause ... |
DB08930 | DB13142 | 1,459 | 841 | [
"DDInter582",
"DDInter274"
] | Dolutegravir | Calcium glubionate anhydrous | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Major | 2 | [
[
[
1459,
25,
841
]
],
[
[
1459,
63,
372
],
[
372,
23,
255
],
[
255,
24,
841
]
],
[
[
1459,
64,
1283
],
[
1283,
24,
255
],
[
255,
24,
... | [
[
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Dolutegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
... | Dolutegravir may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glu... |
DB00074 | DB14711 | 1,309 | 779 | [
"DDInter166",
"DDInter1680"
] | Basiliximab | Smallpox (Vaccinia) Vaccine, Live | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1309,
25,
779
]
],
[
[
1309,
25,
1064
],
[
1064,
25,
779
]
],
[
[
1309,
64,
581
],
[
581,
25,
779
]
],
[
[
1309,
24,
270
],
[
270,
... | [
[
[
"Basiliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Basiliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Basiliximab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Basiliximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a m... |
DB00624 | DB08889 | 1,561 | 350 | [
"DDInter1775",
"DDInter299"
] | Testosterone | Carfilzomib | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Major | 2 | [
[
[
1561,
25,
350
]
],
[
[
1561,
6,
4973
],
[
4973,
45,
350
]
],
[
[
1561,
21,
28762
],
[
28762,
60,
350
]
],
[
[
1561,
63,
482
],
[
482,
... | [
[
[
"Testosterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Testosterone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Carf... | Testosterone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound)
Testosterone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and ... |
DB00365 | DB01177 | 839 | 77 | [
"DDInter842",
"DDInter904"
] | Grepafloxacin | Idarubicin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
839,
25,
77
]
],
[
[
839,
23,
112
],
[
112,
23,
77
]
],
[
[
839,
25,
823
],
[
823,
63,
77
]
],
[
[
839,
24,
543
],
[
543,
24,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Grepafloxacin may lead to a major life threatening interaction when taken with Triclabendazole and Triclabe... |
DB00169 | DB00880 | 386 | 359 | [
"DDInter367",
"DDInter360"
] | Cholecalciferol | Chlorothiazide | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
386,
24,
359
]
],
[
[
386,
24,
1577
],
[
1577,
1,
359
]
],
[
[
386,
25,
1196
],
[
1196,
63,
359
]
],
[
[
386,
75,
1331
],
[
1331,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethi... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Cholecalciferol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a modera... |
DB00209 | DB01036 | 352 | 211 | [
"DDInter1886",
"DDInter1832"
] | Trospium | Tolterodine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
352,
24,
211
]
],
[
[
352,
24,
358
],
[
358,
40,
211
]
],
[
[
352,
24,
128
],
[
128,
24,
211
]
],
[
[
352,
6,
4304
],
[
4304,
45... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Tolterodine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate inter... |
DB01233 | DB01339 | 1,311 | 728 | [
"DDInter1197",
"DDInter1922"
] | Metoclopramide | Vecuronium | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide ad... | Moderate | 1 | [
[
[
1311,
24,
728
]
],
[
[
1311,
63,
1610
],
[
1610,
1,
728
]
],
[
[
1311,
24,
1579
],
[
1579,
40,
728
]
],
[
[
1311,
21,
28766
],
[
28766... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (... |
DB00495 | DB00501 | 139 | 752 | [
"DDInter1961",
"DDInter380"
] | Zidovudine | Cimetidine | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Minor | 0 | [
[
[
139,
23,
752
]
],
[
[
139,
6,
4973
],
[
4973,
45,
752
]
],
[
[
139,
21,
29134
],
[
29134,
60,
752
]
],
[
[
139,
24,
1468
],
[
1468,
... | [
[
[
"Zidovudine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Zidovudine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cimetidine (Compound)
Zidovudine (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponat... |
DB00418 | DB01619 | 536 | 830 | [
"DDInter1650",
"DDInter1441"
] | Secobarbital | Phenindamine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
536,
24,
830
]
],
[
[
536,
24,
537
],
[
537,
40,
830
]
],
[
[
536,
24,
13
],
[
13,
24,
830
]
],
[
[
536,
24,
104
],
[
104,
1,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interactio... |
DB08870 | DB11652 | 850 | 1,155 | [
"DDInter228",
"DDInter1891"
] | Brentuximab vedotin | Tucatinib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
850,
24,
1155
]
],
[
[
850,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
850,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
850,
24,
1613
],
[
1613,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Quinin... |
DB00065 | DB00078 | 581 | 1,172 | [
"DDInter923",
"DDInter898"
] | Infliximab | Ibritumomab tiuxetan | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Major | 2 | [
[
[
581,
25,
1172
]
],
[
[
581,
24,
58
],
[
58,
63,
1172
]
],
[
[
581,
25,
563
],
[
563,
63,
1172
]
],
[
[
581,
64,
1184
],
[
1184,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"A... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan
Infliximab may lead to a major life threatening interaction when taken with Ganciclovir and Ganciclovir ... |
DB01191 | DB01362 | 1,039 | 497 | [
"DDInter518",
"DDInter960"
] | Dexfenfluramine | Iohexol | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1039,
25,
497
]
],
[
[
1039,
64,
318
],
[
318,
25,
497
]
],
[
[
1039,
63,
886
],
[
886,
25,
497
]
],
[
[
1039,
24,
1267
],
[
1267,
... | [
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
... | Dexfenfluramine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may lead to a major life threatening interaction when taken with Iohexol
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a ma... |
DB00792 | DB11859 | 832 | 418 | [
"DDInter1878",
"DDInter230"
] | Tripelennamine | Brexanolone | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
832,
24,
418
]
],
[
[
832,
24,
100
],
[
100,
24,
418
]
],
[
[
832,
63,
85
],
[
85,
24,
418
]
],
[
[
832,
35,
272
],
[
272,
24,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with At... |
DB00497 | DB06273 | 828 | 980 | [
"DDInter1366",
"DDInter1824"
] | Oxycodone | Tocilizumab | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
828,
24,
980
]
],
[
[
828,
64,
597
],
[
597,
24,
980
]
],
[
[
828,
63,
58
],
[
58,
24,
980
]
],
[
[
828,
25,
267
],
[
267,
24,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chloramphenicol"
],
[
"Chlora... | Oxycodone may lead to a major life threatening interaction when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may... |
DB00334 | DB11837 | 867 | 1,297 | [
"DDInter1326",
"DDInter1351"
] | Olanzapine | Osilodrostat | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
867,
24,
1297
]
],
[
[
867,
23,
112
],
[
112,
23,
1297
]
],
[
[
867,
24,
222
],
[
222,
23,
1297
]
],
[
[
867,
1,
623
],
[
623,
2... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and S... |
DB01218 | DB06717 | 1,493 | 875 | [
"DDInter852",
"DDInter778"
] | Halofantrine | Fosaprepitant | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Major | 2 | [
[
[
1493,
25,
875
]
],
[
[
1493,
64,
723
],
[
723,
1,
875
]
],
[
[
1493,
21,
29180
],
[
29180,
60,
875
]
],
[
[
1493,
63,
1101
],
[
1101,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
... | Halofantrine may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Halofantrine (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Halofantrine may cause a mo... |
DB00631 | DB06616 | 372 | 594 | [
"DDInter405",
"DDInter224"
] | Clofarabine | Bosutinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
372,
24,
594
]
],
[
[
372,
63,
883
],
[
883,
1,
594
]
],
[
[
372,
7,
8922
],
[
8922,
45,
594
]
],
[
[
372,
18,
18560
],
[
18560,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Clofarabine (Compound) upregulates SIK1 (Gene) and SIK1 (Gene) is bound by Bosutinib (Compound)
Clofarabine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene)... |
DB00023 | DB00480 | 305 | 1,668 | [
"DDInter127",
"DDInter1035"
] | Asparaginase Escherichia coli | Lenalidomide | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Moderate | 1 | [
[
[
305,
24,
1668
]
],
[
[
305,
25,
770
],
[
770,
40,
1668
]
],
[
[
305,
24,
126
],
[
126,
62,
1668
]
],
[
[
305,
24,
597
],
[
597,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Th... | Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor in... |
DB00539 | DB01267 | 11 | 519 | [
"DDInter1837",
"DDInter1381"
] | Toremifene | Paliperidone | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Major | 2 | [
[
[
11,
25,
519
]
],
[
[
11,
25,
1664
],
[
1664,
1,
519
]
],
[
[
11,
6,
8374
],
[
8374,
45,
519
]
],
[
[
11,
21,
29459
],
[
29459,
6... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paliperidone"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{... | Toremifene may lead to a major life threatening interaction when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paliperidone (Compound)
Toremifene (Compound) causes Skin discolouration (Side Effect) and Skin dis... |
DB01403 | DB12245 | 9 | 823 | [
"DDInter1175",
"DDInter1863"
] | Methotrimeprazine | Triclabendazole | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
9,
24,
823
]
],
[
[
9,
62,
112
],
[
112,
23,
823
]
],
[
[
9,
63,
1010
],
[
1010,
24,
823
]
],
[
[
9,
24,
28
],
[
28,
24,
8... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidaz... | Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00976 | DB08820 | 1,056 | 1,478 | [
"DDInter1758",
"DDInter997"
] | Telithromycin | Ivacaftor | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
1056,
25,
1478
]
],
[
[
1056,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1056,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
1056,
25,
1135
],
[
1... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Iv... | Telithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Telithromycin (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Telithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol... |
DB00035 | DB00836 | 1,314 | 543 | [
"DDInter507",
"DDInter1088"
] | Desmopressin | Loperamide | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
1314,
24,
543
]
],
[
[
1314,
24,
704
],
[
704,
40,
543
]
],
[
[
1314,
24,
675
],
[
675,
24,
543
]
],
[
[
1314,
21,
28722
],
[
28722,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Loperamide (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate intera... |
DB01036 | DB01142 | 211 | 1,264 | [
"DDInter1832",
"DDInter593"
] | Tolterodine | Doxepin | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
211,
24,
1264
]
],
[
[
211,
24,
401
],
[
401,
24,
1264
]
],
[
[
211,
63,
832
],
[
832,
24,
1264
]
],
[
[
211,
1,
11296
],
[
11296,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and... |
DB06595 | DB14509 | 1,491 | 1,399 | [
"DDInter1214",
"DDInter1081"
] | Midostaurin | Lithium carbonate | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1491,
24,
1399
]
],
[
[
1491,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
1491,
63,
1374
],
[
1374,
24,
1399
]
],
[
[
1491,
64,
609
],
[
609... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Abirateron... |
DB00146 | DB00910 | 160 | 1,041 | [
"DDInter265",
"DDInter1394"
] | Calcifediol | Paricalcitol | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Major | 2 | [
[
[
160,
25,
1041
]
],
[
[
160,
36,
386
],
[
386,
25,
1041
]
],
[
[
160,
40,
1113
],
[
1113,
1,
1041
]
],
[
[
160,
40,
11457
],
[
11457,
... | [
[
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
]
],
[
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalc... | Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Calcifediol (Compound) resembles Calcitriol (Compound) and Calcit... |
DB00872 | DB00911 | 1,080 | 458 | [
"DDInter438",
"DDInter1811"
] | Conivaptan | Tinidazole | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
1080,
24,
458
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
458
]
],
[
[
1080,
21,
28882
],
[
28882,
60,
458
]
],
[
[
1080,
24,
310
],
[
310,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tinidazole (Compound)
Conivaptan (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tinidazole (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases w... |
DB00585 | DB04868 | 1,127 | 478 | [
"DDInter1309",
"DDInter1293"
] | Nizatidine | Nilotinib | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1127,
24,
478
]
],
[
[
1127,
23,
1468
],
[
1468,
63,
478
]
],
[
[
1127,
6,
4973
],
[
4973,
45,
478
]
],
[
[
1127,
18,
7248
],
[
7248,
... | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
... | Nizatidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nizatidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Nizatidine (Compound) down... |
DB00352 | DB04835 | 482 | 1,655 | [
"DDInter1814",
"DDInter1125"
] | Tioguanine | Maraviroc | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
482,
24,
1655
]
],
[
[
482,
21,
28868
],
[
28868,
60,
1655
]
],
[
[
482,
24,
1419
],
[
1419,
24,
1655
]
],
[
[
482,
24,
1468
],
[
1468... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is cau... | Tioguanine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Maraviroc (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
... |
DB01576 | DB06723 | 93 | 115 | [
"DDInter526",
"DDInter58"
] | Dextroamphetamine | Aluminum hydroxide | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
93,
24,
115
]
],
[
[
93,
21,
28643
],
[
28643,
60,
115
]
],
[
[
93,
63,
401
],
[
401,
23,
115
]
],
[
[
93,
1,
939
],
[
939,
24,
... | [
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Dextroamphetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u}... | Dextroamphetamine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects... |
DB00421 | DB01088 | 443 | 714 | [
"DDInter1707",
"DDInter908"
] | Spironolactone | Iloprost | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
443,
24,
714
]
],
[
[
443,
23,
1479
],
[
1479,
24,
714
]
],
[
[
443,
63,
1648
],
[
1648,
24,
714
]
],
[
[
443,
24,
1450
],
[
1450,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Spironolactone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
... | Spironolactone may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00443 | DB06643 | 251 | 1,136 | [
"DDInter195",
"DDInter500"
] | Betamethasone | Denosumab | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
251,
24,
1136
]
],
[
[
251,
24,
1316
],
[
1316,
63,
1136
]
],
[
[
251,
24,
1419
],
[
1419,
24,
1136
]
],
[
[
251,
63,
1648
],
[
1648,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Ima... |
DB01099 | DB09498 | 1,272 | 810 | [
"DDInter744",
"DDInter1715"
] | Flucytosine | Strontium chloride Sr-89 | A fluorinated cytosine analog that is used as an antifungal agent. | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
1272,
24,
810
]
],
[
[
1272,
63,
1555
],
[
1555,
24,
810
]
],
[
[
1272,
62,
1224
],
[
1224,
24,
810
]
],
[
[
1272,
24,
546
],
[
546,
... | [
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin... | Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Flucytosine may cause a minor interaction that can limit clinical effects when taken with Cytar... |
DB10315 | DB11730 | 1,137 | 351 | [
"DDInter1127",
"DDInter1588"
] | Measles virus vaccine live attenuated | Ribociclib | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1137,
25,
351
]
],
[
[
1137,
64,
310
],
[
310,
24,
351
]
],
[
[
1137,
25,
738
],
[
738,
63,
351
]
],
[
[
1137,
63,
617
],
[
617,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cab... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken ... |
DB00960 | DB01067 | 887 | 959 | [
"DDInter1471",
"DDInter826"
] | Pindolol | Glipizide | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
887,
24,
959
]
],
[
[
887,
63,
245
],
[
245,
40,
959
]
],
[
[
887,
24,
1411
],
[
1411,
1,
959
]
],
[
[
887,
21,
28698
],
[
28698,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Pi... |
DB00019 | DB01206 | 1,257 | 37 | [
"DDInter1405",
"DDInter1086"
] | Pegfilgrastim | Lomustine | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1257,
24,
37
]
],
[
[
1257,
24,
147
],
[
147,
23,
37
]
],
[
[
1257,
24,
141
],
[
141,
24,
37
]
],
[
[
1257,
24,
385
],
[
385,
63... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and ... |
DB09268 | DB11228 | 1,662 | 721 | [
"DDInter1464",
"DDInter1184"
] | Picosulfuric acid | Methylcellulose | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum... | Minor | 0 | [
[
[
1662,
23,
721
]
],
[
[
1662,
62,
16
],
[
16,
23,
721
]
],
[
[
1662,
63,
355
],
[
355,
24,
721
]
],
[
[
1662,
62,
16
],
[
16,
62,... | [
[
[
"Picosulfuric acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"... | Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Lact... |
DB00959 | DB14723 | 1,486 | 159 | [
"DDInter1191",
"DDInter1026"
] | Methylprednisolone | Larotrectinib | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1486,
24,
159
]
],
[
[
1486,
24,
1375
],
[
1375,
24,
159
]
],
[
[
1486,
62,
307
],
[
307,
24,
159
]
],
[
[
1486,
24,
1412
],
[
1412,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamuli... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Modafi... |
DB00909 | DB08899 | 306 | 129 | [
"DDInter1971",
"DDInter649"
] | Zonisamide | Enzalutamide | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
306,
24,
129
]
],
[
[
306,
24,
918
],
[
918,
1,
129
]
],
[
[
306,
6,
8374
],
[
8374,
45,
129
]
],
[
[
306,
21,
28703
],
[
28703,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Zonisamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Zonisamide (Compound) causes Pruritus (Side Effect) and Pr... |
DB01224 | DB09280 | 623 | 1,604 | [
"DDInter1553",
"DDInter1101"
] | Quetiapine | Lumacaftor | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
623,
25,
1604
]
],
[
[
623,
63,
473
],
[
473,
24,
1604
]
],
[
[
623,
64,
593
],
[
593,
24,
1604
]
],
[
[
623,
24,
1281
],
[
1281,
... | [
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglini... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Quetiapine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause ... |
DB00619 | DB00820 | 1,419 | 402 | [
"DDInter909",
"DDInter1736"
] | Imatinib | Tadalafil | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Moderate | 1 | [
[
[
1419,
24,
402
]
],
[
[
1419,
6,
8374
],
[
8374,
45,
402
]
],
[
[
1419,
21,
28669
],
[
28669,
60,
402
]
],
[
[
1419,
24,
159
],
[
159,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tadalafil (Compound)
Imatinib (Compound) causes Conjunctivitis (Side Effect) and Conjunctivitis (Side Effect) is caused by Tadalafil (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and... |
DB00295 | DB14881 | 475 | 180 | [
"DDInter1244",
"DDInter1329"
] | Morphine | Oliceridine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
475,
25,
180
]
],
[
[
475,
24,
401
],
[
401,
24,
180
]
],
[
[
475,
63,
1314
],
[
1314,
24,
180
]
],
[
[
475,
25,
593
],
[
593,
2... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazin... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Des... |
DB00816 | DB11837 | 1,674 | 1,297 | [
"DDInter1346",
"DDInter1351"
] | Orciprenaline | Osilodrostat | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1674,
24,
1297
]
],
[
[
1674,
24,
222
],
[
222,
23,
1297
]
],
[
[
1674,
24,
623
],
[
623,
24,
1297
]
],
[
[
1674,
63,
1555
],
[
1555,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine an... |
DB00529 | DB01082 | 789 | 1,448 | [
"DDInter779",
"DDInter1713"
] | Foscarnet | Streptomycin | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Major | 2 | [
[
[
789,
25,
1448
]
],
[
[
789,
6,
10612
],
[
10612,
45,
1448
]
],
[
[
789,
21,
29327
],
[
29327,
60,
1448
]
],
[
[
789,
24,
1272
],
[
127... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
]
],
[
[
"Foscarnet",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Strep... | Foscarnet (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Streptomycin (Compound)
Foscarnet (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Streptomycin (Compound)
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Flucytos... |
DB00582 | DB01001 | 1,622 | 688 | [
"DDInter1946",
"DDInter1632"
] | Voriconazole | Salbutamol | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1622,
24,
688
]
],
[
[
1622,
25,
455
],
[
455,
24,
688
]
],
[
[
1622,
24,
1148
],
[
1148,
63,
688
]
],
[
[
1622,
6,
8374
],
[
8374,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmet... | Voriconazole may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline ma... |
DB12267 | DB12364 | 1,476 | 1,421 | [
"DDInter233",
"DDInter200"
] | Brigatinib | Betrixaban | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1476,
24,
1421
]
],
[
[
1476,
64,
1091
],
[
1091,
24,
1421
]
],
[
[
1476,
63,
1513
],
[
1513,
24,
1421
]
],
[
[
1476,
24,
1339
],
[
13... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir... | Brigatinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast and Apremilast may cause ... |
DB06605 | DB11979 | 1,409 | 1,320 | [
"DDInter108",
"DDInter625"
] | Apixaban | Elagolix | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1409,
24,
1320
]
],
[
[
1409,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
1409,
63,
79
],
[
79,
24,
1320
]
],
[
[
1409,
25,
129
],
[
129,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib... |
DB00305 | DB00544 | 377 | 970 | [
"DDInter1232",
"DDInter757"
] | Mitomycin | Fluorouracil | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Major | 2 | [
[
[
377,
25,
970
]
],
[
[
377,
5,
11616
],
[
11616,
44,
970
]
],
[
[
377,
7,
2969
],
[
2969,
46,
970
]
],
[
[
377,
21,
28719
],
[
28719,
... | [
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluorouracil"
]
],
[
[
"Mitomycin",
"{u} (Compound) treats {v} (Disease)",
"stomach cancer"
],
[
"stomach cancer",
"{u} (Disease) is treated by {v} (C... | Mitomycin (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Fluorouracil (Compound)
Mitomycin (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Fluorouracil (Compound)
Mitomycin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Fluorourac... |
DB00719 | DB11130 | 1,219 | 407 | [
"DDInter149",
"DDInter1344"
] | Azatadine | Opium | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1219,
24,
407
]
],
[
[
1219,
63,
558
],
[
558,
24,
407
]
],
[
[
1219,
24,
1190
],
[
1190,
24,
407
]
],
[
[
1219,
24,
418
],
[
418,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolp... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine and Ketamine may cause ... |
DB00331 | DB00436 | 1,645 | 323 | [
"DDInter1164",
"DDInter179"
] | Metformin | Bendroflumethiazide | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Moderate | 1 | [
[
[
1645,
24,
323
]
],
[
[
1645,
24,
1014
],
[
1014,
1,
323
]
],
[
[
1645,
21,
28766
],
[
28766,
60,
323
]
],
[
[
1645,
24,
126
],
[
126,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Metformin (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Bendroflumethiazide (Compound)
Metformin may cause ... |
DB00472 | DB00619 | 758 | 1,419 | [
"DDInter758",
"DDInter909"
] | Fluoxetine | Imatinib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
758,
24,
1419
]
],
[
[
758,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
758,
7,
3727
],
[
3727,
46,
1419
]
],
[
[
758,
21,
29016
],
[
29016,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluoxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Fluoxetine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Imatinib (Compound)
Fluoxetine (Compound) causes Menorrhagia (Side Effect) and Menorrhagia (Side Effect) is caused by Imatinib (Compound)
Fluoxetine may... |
DB01208 | DB11718 | 945 | 927 | [
"DDInter1705",
"DDInter640"
] | Sparfloxacin | Encorafenib | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
945,
25,
927
]
],
[
[
945,
62,
112
],
[
112,
23,
927
]
],
[
[
945,
24,
720
],
[
720,
24,
927
]
],
[
[
945,
62,
372
],
[
372,
24,... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil an... |
DB00397 | DB01367 | 1,466 | 1,163 | [
"DDInter1458",
"DDInter1572"
] | Phenylpropanolamine | Rasagiline | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
1466,
24,
1163
]
],
[
[
1466,
6,
7950
],
[
7950,
45,
1163
]
],
[
[
1466,
21,
28963
],
[
28963,
60,
1163
]
],
[
[
1466,
24,
590
],
[
59... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound b... | Phenylpropanolamine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rasagiline (Compound)
Phenylpropanolamine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Rasagiline (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00656 | DB09078 | 827 | 1,228 | [
"DDInter1851",
"DDInter1036"
] | Trazodone | Lenvatinib | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
827,
24,
1228
]
],
[
[
827,
23,
112
],
[
112,
23,
1228
]
],
[
[
827,
24,
609
],
[
609,
24,
1228
]
],
[
[
827,
25,
1264
],
[
1264,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Trazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cl... |
DB00876 | DB00877 | 1,414 | 629 | [
"DDInter658",
"DDInter1678"
] | Eprosartan | Sirolimus | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1414,
24,
629
]
],
[
[
1414,
21,
29203
],
[
29203,
60,
629
]
],
[
[
1414,
63,
167
],
[
167,
24,
629
]
],
[
[
1414,
24,
549
],
[
549,
... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Eprosartan",
"{u} (Compound) causes {v} (Side Effect)",
"Aspartate aminotransferase increased"
],
[
"Aspartate aminotra... | Eprosartan (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate inter... |
DB06643 | DB08880 | 1,136 | 1,510 | [
"DDInter500",
"DDInter1771"
] | Denosumab | Teriflunomide | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
1136,
24,
1510
]
],
[
[
1136,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
1136,
24,
36
],
[
36,
25,
1510
]
],
[
[
1136,
63,
147
],
[
147,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin ... |
DB00176 | DB06209 | 529 | 256 | [
"DDInter770",
"DDInter1508"
] | Fluvoxamine | Prasugrel | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
529,
24,
256
]
],
[
[
529,
6,
10215
],
[
10215,
45,
256
]
],
[
[
529,
21,
28681
],
[
28681,
60,
256
]
],
[
[
529,
24,
1215
],
[
1215,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound... | Fluvoxamine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Fluvoxamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with La... |
DB01075 | DB11963 | 1,376 | 1,045 | [
"DDInter569",
"DDInter465"
] | Diphenhydramine | Dacomitinib | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Moderate | 1 | [
[
[
1376,
24,
1045
]
],
[
[
1376,
63,
479
],
[
479,
23,
1045
]
],
[
[
1376,
63,
1664
],
[
1664,
24,
1045
]
],
[
[
1376,
24,
1592
],
[
1592... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone an... |
DB00262 | DB11793 | 552 | 738 | [
"DDInter302",
"DDInter1297"
] | Carmustine | Niraparib | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
552,
24,
738
]
],
[
[
552,
24,
663
],
[
663,
24,
738
]
],
[
[
552,
63,
1253
],
[
1253,
24,
738
]
],
[
[
552,
25,
770
],
[
770,
2... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Pal... |
DB00188 | DB01309 | 168 | 1,254 | [
"DDInter222",
"DDInter933"
] | Bortezomib | Insulin glulisine | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
168,
24,
1254
]
],
[
[
168,
24,
1033
],
[
1033,
63,
1254
]
],
[
[
168,
23,
1094
],
[
1094,
63,
1254
]
],
[
[
168,
24,
1645
],
[
1645,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin and Me... |
DB00604 | DB00843 | 1,425 | 479 | [
"DDInter385",
"DDInter583"
] | Cisapride | Donepezil | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
1425,
24,
479
]
],
[
[
1425,
25,
843
],
[
843,
1,
479
]
],
[
[
1425,
6,
12523
],
[
12523,
45,
479
]
],
[
[
1425,
25,
760
],
[
760,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenaz... | Cisapride may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound)
Cisapride (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound)
Cisapride may lead to a major life threatening interaction when taken with Cobi... |
DB00046 | DB00224 | 1,179 | 215 | [
"DDInter940",
"DDInter917"
] | Insulin lispro | Indinavir | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Moderate | 1 | [
[
[
1179,
24,
215
]
],
[
[
1179,
24,
798
],
[
798,
1,
215
]
],
[
[
1179,
24,
303
],
[
303,
62,
215
]
],
[
[
1179,
24,
1151
],
[
1151,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Indinavir (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate ma... |
DB00443 | DB01018 | 251 | 1,364 | [
"DDInter195",
"DDInter847"
] | Betamethasone | Guanfacine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
251,
24,
1364
]
],
[
[
251,
24,
1512
],
[
1512,
1,
1364
]
],
[
[
251,
6,
8374
],
[
8374,
45,
1364
]
],
[
[
251,
21,
28757
],
[
28757,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Guanfacine (Compound)
Betamethasone (Compound) causes Dyspepsia (Side Effect) and ... |
DB06603 | DB06643 | 39 | 1,136 | [
"DDInter1387",
"DDInter500"
] | Panobinostat | Denosumab | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
39,
24,
1136
]
],
[
[
39,
64,
1213
],
[
1213,
24,
1136
]
],
[
[
39,
63,
1419
],
[
1419,
24,
1136
]
],
[
[
39,
25,
1510
],
[
1510,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatini... | Panobinostat may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a m... |
DB00911 | DB12500 | 458 | 283 | [
"DDInter1811",
"DDInter714"
] | Tinidazole | Fedratinib | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
458,
24,
283
]
],
[
[
458,
24,
351
],
[
351,
23,
283
]
],
[
[
458,
24,
1339
],
[
1339,
62,
283
]
],
[
[
458,
24,
1580
],
[
1580,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotr... |
DB00529 | DB06603 | 789 | 39 | [
"DDInter779",
"DDInter1387"
] | Foscarnet | Panobinostat | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
789,
25,
39
]
],
[
[
789,
23,
112
],
[
112,
23,
39
]
],
[
[
789,
24,
455
],
[
455,
24,
39
]
],
[
[
789,
24,
720
],
[
720,
63,
... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Foscarnet",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salm... |
DB06595 | DB06788 | 1,491 | 1,616 | [
"DDInter1214",
"DDInter864"
] | Midostaurin | Histrelin | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1491,
24,
1616
]
],
[
[
1491,
62,
112
],
[
112,
23,
1616
]
],
[
[
1491,
63,
1664
],
[
1664,
24,
1616
]
],
[
[
1491,
24,
603
],
[
603,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Midostaurin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Ri... |
DB00776 | DB01006 | 1,335 | 300 | [
"DDInter1360",
"DDInter1040"
] | Oxcarbazepine | Letrozole | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Moderate | 1 | [
[
[
1335,
24,
300
]
],
[
[
1335,
6,
8374
],
[
8374,
45,
300
]
],
[
[
1335,
7,
2384
],
[
2384,
46,
300
]
],
[
[
1335,
21,
28646
],
[
28646,... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Oxcarbazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Letrozole (Compound)
Oxcarbazepine (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Letrozole (Compound)
Oxcarbazepine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disor... |
DB00078 | DB00758 | 1,172 | 1,347 | [
"DDInter898",
"DDInter413"
] | Ibritumomab tiuxetan | Clopidogrel | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Major | 2 | [
[
[
1172,
25,
1347
]
],
[
[
1172,
25,
1018
],
[
1018,
25,
1347
]
],
[
[
1172,
23,
539
],
[
539,
62,
1347
]
],
[
[
1172,
25,
1338
],
[
1338... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Tic... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may caus... |
DB00348 | DB01141 | 254 | 692 | [
"DDInter1300",
"DDInter1208"
] | Nitisinone | Micafungin | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. | Moderate | 1 | [
[
[
254,
24,
692
]
],
[
[
254,
21,
29742
],
[
29742,
60,
692
]
],
[
[
254,
24,
351
],
[
351,
63,
692
]
],
[
[
254,
21,
29742
],
[
29742,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Micafungin"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatomegaly"
],
[
"Hepatomegaly",
"{u} (Side Effect) i... | Nitisinone (Compound) causes Hepatomegaly (Side Effect) and Hepatomegaly (Side Effect) is caused by Micafungin (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with M... |
DB01259 | DB11915 | 392 | 1,293 | [
"DDInter1024",
"DDInter1909"
] | Lapatinib | Valbenazine | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
392,
24,
1293
]
],
[
[
392,
62,
112
],
[
112,
23,
1293
]
],
[
[
392,
24,
710
],
[
710,
63,
1293
]
],
[
[
392,
63,
521
],
[
521,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Bini... |
DB05273 | DB11952 | 507 | 800 | [
"DDInter1638",
"DDInter612"
] | Samarium (153Sm) lexidronam | Duvelisib | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
507,
25,
800
]
],
[
[
507,
25,
310
],
[
310,
24,
800
]
],
[
[
507,
64,
663
],
[
663,
24,
800
]
],
[
[
507,
24,
270
],
[
270,
63,... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Methotrexate and... |
DB00694 | DB14509 | 51 | 1,399 | [
"DDInter485",
"DDInter1081"
] | Daunorubicin | Lithium carbonate | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
51,
24,
1399
]
],
[
[
51,
63,
589
],
[
589,
23,
1399
]
],
[
[
51,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
51,
63,
1010
],
[
1010,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone an... |
DB00189 | DB04837 | 459 | 649 | [
"DDInter691",
"DDInter407"
] | Ethchlorvynol | Clofedanol | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
459,
24,
649
]
],
[
[
459,
24,
1376
],
[
1376,
24,
649
]
],
[
[
459,
24,
1609
],
[
1609,
63,
649
]
],
[
[
459,
25,
475
],
[
475,
... | [
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Pento... |
DB00054 | DB00159 | 1,432 | 940 | [
"DDInter6",
"DDInter903"
] | Abciximab | Icosapent | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Moderate | 1 | [
[
[
1432,
24,
940
]
],
[
[
1432,
25,
500
],
[
500,
63,
940
]
],
[
[
1432,
64,
582
],
[
582,
24,
940
]
],
[
[
1432,
24,
1061
],
[
1061,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Icosapent"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
... | Abciximab may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Icosapent
Abciximab may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a moderate interacti... |
DB00444 | DB00995 | 63 | 1,112 | [
"DDInter1765",
"DDInter139"
] | Teniposide | Auranofin | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Moderate | 1 | [
[
[
63,
24,
1112
]
],
[
[
63,
7,
2067
],
[
2067,
45,
1112
]
],
[
[
63,
7,
3576
],
[
3576,
46,
1112
]
],
[
[
63,
18,
8781
],
[
8781,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Teniposide",
"{u} (Compound) upregulates {v} (Gene)",
"IKBKB"
],
[
"IKBKB",
"{u} (Gene) is bound by {v} (Compound... | Teniposide (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Auranofin (Compound)
Teniposide (Compound) upregulates ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Auranofin (Compound)
Teniposide (Compound) downregulates ST7 (Gene) and ST7 (Gene) is upregulated by Auranofin (Compound)
Teniposide (Compoun... |
DB00782 | DB01075 | 1,123 | 1,376 | [
"DDInter1535",
"DDInter569"
] | Propantheline | Diphenhydramine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
1123,
24,
1376
]
],
[
[
1123,
63,
128
],
[
128,
24,
1376
]
],
[
[
1123,
24,
832
],
[
832,
24,
1376
]
],
[
[
1123,
40,
11241
],
[
11241... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbromphenirami... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken... |
DB00682 | DB00945 | 126 | 1,479 | [
"DDInter1951",
"DDInter20"
] | Warfarin | Acetylsalicylic acid | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Major | 2 | [
[
[
126,
25,
1479
]
],
[
[
126,
1,
345
],
[
345,
40,
1479
]
],
[
[
126,
63,
316
],
[
316,
40,
1479
]
],
[
[
126,
25,
1338
],
[
1338,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Salsalate"
],
[
"Salsalate",
"{u} (Compound) resembles {v} (Comp... | Warfarin (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Acetylsalicylic acid (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide and Nitazoxanide (Compound) resembles Acetylsalicylic acid (Compound)
Warfarin may lead to a major l... |
DB00443 | DB00598 | 251 | 1,523 | [
"DDInter195",
"DDInter1013"
] | Betamethasone | Labetalol | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
251,
24,
1523
]
],
[
[
251,
23,
455
],
[
455,
64,
1523
]
],
[
[
251,
24,
935
],
[
935,
1,
1523
]
],
[
[
251,
23,
1148
],
[
1148,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[... | Betamethasone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compou... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.